Psoriasis Risk With Immune Checkpoint Inhibitors.

ABSTRACT:

Importance

Immune checkpoint inhibitors (ICIs) are recognized as revolutionary cancer therapies but have raised concerns about immune-related adverse events, including the development of autoimmune diseases.

Objective

To evaluate the psoriasis risk associated with the use of ICIs in patients with cancer.

Design, setting, and participants

This nationwide cohort study with a target trial emulation design used data from the Taiwan National Health Insurance database and the Taiwan Cancer Registry. The participants included were patients who received antineoplastic medications for cancer at stages III and IV between January 1, 2019, and June 30, 2021. Data were analyzed from May 2023 to July 2024.

Exposures

Patients treated with ICIs were classified as ICI users, wh

SUBMITTER: To SY 

PROVIDER: S-EPMC11541743 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature